The Breville CEO sale is a more interesting tale. CEO Jim Clayton sold approximately 218,000 shares at an average price of $32.46 in September 2025, for just over $7mn — a disposal representing a meaningful 52% of his entire holding. The timing proved well-timed for Clayton, with the stock quickly declining ~18%. The shares have continued weakening through the first half of 2026, trading in a large $24–$29 range, well below where the CEO cashed out.
- H1 FY2026 results showed record sales of $1.1 billion with 10.1% revenue growth, but EBIT remained flat at $145.8 million with gross margin declining — a result that explained the market’s muted response and subsequent de-rating.
The subsequent operating performance helps explain the weakness. Breville’s H1 FY26 result delivered record sales of $1.1 billion and revenue growth of 10.1%, but EBIT was broadly flat at $145.8 million as gross margins declined. The top-line result was solid, but the lack of earnings leverage reinforced concerns around cost pressures and ultimately justified a lower valuation multiple.
The sale was neither illegal nor scandalous, and no specific explanation was provided. However, shareholders who followed Clayton’s lead and reduced exposure around $32 have fared materially better than those who held. The August full-year result now looms as the next major test of whether BRG can stabilise margins and begin rebuilding confidence.
The sale wasn’t illegal or scandalous, and came with no explanatory statement, but shareholders who followed the CEO’s lead and trimmed/sold at $32 have been well ahead of those who held. The August full-year result will be the next line in the sand for whether BRG can reclaim those levels.
- Jul 2023 – Aug 2023 (~A$20 → A$25): BRG surged 14% in August 2023 — its best day since March 2020, after FY23 net income beat consensus estimates.
- Feb 2024 (~A$27 → A$24): H1 FY24 revenue missed estimates by ~4.5% with soft EBIT guidance, sending the stock down as much as 13%. No director selling was identified ahead of this result.
- Aug 2024 – Jan 2025 (~A$34 → A$38): BRG re-rated to multi-year highs after FY24 net income beat estimates and global product sales re-accelerated in H2.
- Feb 2025 – Apr 2025 (~A$35 → A$29): The stock de-rated on tariff concerns; BRG has significant US exposure, falling 5.8% on 2 April 2025 as Trump tariff announcements hit consumer discretionary names.
- Feb 2026: H1 FY26 EPS missed estimates; stock fell 5.5%, its worst day in almost nine months. Challenger subsequently reduced its stake in March 2026.
At this stage, we see no obvious catalyst for Market Matters to consider BRG. Earnings growth is expected to remain modest over the next two years, while the stock still trades on approximately 33x earnings. Without a clear recovery in margins or a material acceleration in profit growth, that valuation remains difficult to justify.
MM is neutral towards BRG around $31
Add To Hit List
